Last updated: March 4, 2025
Sponsor: University of Pittsburgh
Overall Status: Active - Recruiting
Phase
N/A
Condition
Neuronal Ceroid Lipofuscinoses (Ncl)
Multiple Sclerosis
Gaucher Disease
Treatment
Hematopoetic Stem Cell Transplantation
Palliative Care
Clinical Study ID
NCT03333200
STUDY19020318
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Any patient with a genetic neurodegenerative disorder
Exclusion
Exclusion Criteria:
- none
Study Design
Total Participants: 1500
Treatment Group(s): 2
Primary Treatment: Hematopoetic Stem Cell Transplantation
Phase:
Study Start date:
January 11, 2012
Estimated Completion Date:
January 31, 2035
Study Description
Connect with a study center
The Program for the Study of Neurodevelopment in Rare Disorders, Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania 15224
United StatesActive - Recruiting
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania 15224
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.